International aid groups promoting gold-standard anti-malarial treatments subsidize each pharmaceutical companies equally. The goal is to reduce the price consumers ultimately pay, encouraging more of them to choose the most effective drugs. While in general equal subsidies are still somewhat inefficient, that compromise is not as bad as it might seem, according a new study. Even under the worst theoretical conditions, an equal subsidy policy still gets at least half the treatments out the door.